US20260324608
2026-10-22
Human necessities
A01K67/0276
The patent application outlines a method for genetically modifying pigs to serve as transgenic donor animals for xenotransplantation, which involves transplanting organs or tissues from one species to another. By incorporating human transgenes into pigs, the application aims to enhance the long-term survival of transplanted pig organs in human recipients. The transgenes are activated only when the pig's corresponding endogenous genes are knocked out, allowing the donor pig to maintain normal health until the time of transplantation.
The genetic modification involves creating a "genetic switch" that triggers the expression of human transgenes, such as cytokine receptors or adhesion molecules, when the pig's native gene is knocked out. This approach helps ensure that the human transgene operates under the control of the pig's native regulatory sequences, allowing for physiological expression. The knockout process is facilitated by conditional knockout alleles, which can be manipulated to activate the human transgenes at the desired time.
The application includes a sequence listing in XML format, detailing the specific genetic sequences involved. The knockout alleles are flanked by LoxP sequences and can be targeted by an inducible Cre recombinase, which is activated by specific drugs like doxycycline or tamoxifen. This inducible system allows for precise control over the timing of gene knockout and transgene expression, ensuring that the transgenic pigs remain healthy until the organs are harvested for transplantation.
The genetically modified pigs can provide a range of grafts, including organs like the heart, kidney, liver, and tissues such as bone marrow and hematopoietic stem cells. By using pigs as donor animals, the application addresses the current shortage of human organ donors and aims to reduce the need for lifelong, toxic immunosuppressive therapy in transplant recipients. The introduction of human transgenes is intended to promote immune tolerance and improve the durability of transplanted tissues.
The approach described in the patent application could significantly enhance the feasibility and success of xenotransplantation, potentially transforming the field of organ transplantation. By overcoming the limitations of chronic rejection and ensuring the health of donor pigs, this method offers a promising solution to the organ donor shortage. The application also provides a framework for further research and development in the area of genetic modification for medical purposes.